Patent ID: 9669050
Date: 2017-06-06
CPC Classifications: A23L,A23V,A61K,A61P,C07H

Claim:
1. A method for treatment of a human having or at risk of developing hyperlipidemia, fatty liver, atherosclerosis, or obesity comprising administering a composition comprising sialyllactose, which is a-NeuNAc-(2→3)-β-D-Gal-(1→4)-D-Glc or a-NeuNAc-(2-6)-β-D-Gal-(1→4)-D-Glc, or a pharmaceutically acceptable salt thereof, in an amount that is effective for said treatment to a human in need of such treatment, wherein the effective amount is in the range of 0.001-100 mg/kg of the subject's body weight per day.